Clarius Group LLC’s Adaptive Biotechnologies ADPT Stock Holding History

Clarius Group LLC’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-23,824	Closed	-$182K	–	511
2022 Q4	$182K	Sell	23,824 -6,926	-23%	-$53.9K	0.02%	487
2022 Q3	$219K	Buy	30,750 +3,610	+13%	+$34K	0.02%	424
2022 Q2	$220K	Buy	27,140 +16,461	+154%	+$145K	0.02%	415
2022 Q1	$300K	Hold	10,679	–	–	0.02%	359
2021 Q4	$300K	Sell	10,679 -20,000	-65%	-$613K	0.02%	359
2021 Q3	$1.04M	Hold	30,679	–	–	0.09%	119
2021 Q2	$1.25M	Buy	30,679 +5,679	+23%	+$221K	0.11%	108
2021 Q1	$1.01M	Hold	25,000	–	–	0.1%	108
2020 Q4	$1.48M	Sell	25,000 -4,596	-16%	-$237K	0.16%	73
2020 Q3	$1.44M	Hold	29,596	–	–	0.18%	60
2020 Q2	$1.43M	Hold	29,596	–	–	0.2%	61
2020 Q1	$822K	Sell	29,596 -10,000	-25%	-$279K	0.16%	79
2019 Q4	$1.17M	Buy	+39,596	New	+$1.14M	0.19%	66

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BWLSA

Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Clarius Group LLC's ADPT Position: Q1 2023 in Review

Clarius Group LLC sold out of Adaptive Biotechnologies (ADPT) in Q1 2023, closing a stake of 23,824 shares — an estimated $182K sold.

Clarius Group LLC first reported a position in ADPT in Q4 2019 and held it in 13 quarters. The position peaked at $1.48M in Q4 2020. 226 funds tracked by Wall St. Rank hold ADPT as of Q1 2023.

Clarius Group LLC reported no remaining Adaptive Biotechnologies position as of Q1 2023 after selling out during the quarter.
Clarius Group LLC sold 23,824 Adaptive Biotechnologies shares in Q1 2023, an estimated $182K.
Clarius Group LLC first reported a position in Adaptive Biotechnologies in Q4 2019 and held it in 13 quarters.
Clarius Group LLC's Adaptive Biotechnologies position peaked at $1.48M in Q4 2020.
226 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2023.

Based on Clarius Group LLC's 13F filing for Q1 2023, filed 17 Apr 2023.